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Background: Some reports have documented the coexistence of Hepatitis B surfage Antigen (HBsAg) and anti-HBsAg
antibodies (HBsAb) in patients with chronic hepatitis B (CHB), often in the absence of amino acid substitutions in the
HBsAg sequences of the Hepatitis B Virus (HBV) genome able to explain an immunological escape variant.
HBV genome has a very compact coding organization, with four partially overlapping open reading frames (ORFs).
Because the reverse transcriptase region (rt) of HBV polymerase overlaps the HBsAg ORF, it is possible that some
mutations in the HBsAg region correspond to mutations in the rt ORF, conferring resistance to current antiviral
therapies.
This unique case explores the response to antiviral therapies of a CHB with concurrent HBsAg and HBsAb positivity, and
analyse the clinical implications of possible mutations in rt and HBsAg ORFs.
Case presentation: Here we describe the case of a 59 year-old Italian man suffering from Hepatitis B envelope
Antigen (HBeAg) positive CHB with concurrent HBsAb positivity. By ultra-deep pyro-sequencing (UDPS) technique,
mutations conferring immunological escape or resistance to antiviral therapies were found neither in HBsAg nor in HBV
rt ORFs, respectively.
The patient was unsuccessfully treated with interferon, adefovir monotherapy and adefovir plus entecavir combination.
Surprisingly, during entecavir plus tenofovir combination, anti-HBe seroconversion and HBsAg loss were observed, while
the titer of HBsAb persisted.
Conclusions: Concurrent HBsAg/HBsAb positivity in active CHB is a clinical and virological dilemma. In this setting,
there are not consistent data about the response to conventional therapies and the immunological balance between
host and virus remains so far unexplained. This is, to our knowledge, the first case described of a CHB with HBsAg/
HBsAb positivity, wild type for clinically relevant mutations in HBsAg and rt ORFs, successfully treated with a
combination of nucleot(s)ide analogues (NAs).
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Hepatitis B Virus (HBV) can cause a self-limiting acute in-
fection or a chronic hepatitis, depending on the inter-
action between the host’s immune system and the virus.
Typically, the sign of HBV infection is the presence of
Hepatitis B Surface Antigen (HBsAg) in the blood. On the
other hand, the appearance of the neutralizing antibodies
against HBsAg (HBsAb) usually indicates resolution of in-
fection, both spontaneously and after therapy [1].
In this simple virological scenario, some reports have doc-
umented the coexistence of HBsAg and HBsAb in some pa-
tients with chronic hepatitis B (CHB), often in the absence
of amino acid substitutions in the HBsAg sequence able
to explain the escape of HBV from the HBsAb immune
control [2,3]. HBV genome has a very compact coding
organization, with four partially overlapping open reading
frames (ORFs). Because the reverse transcriptase (rt) region
of HBV polymerase overlaps the HBsAg ORF, it is possible
that mutations in the HBsAg region correspond to muta-
tions in the rt ORF, conferring resistance to nucleos(t)ide
analogues (NAs) [4,5]. In addition, due to the quasispecies
nature of the HBV genome in each infected individual, some
mutations may be present in minor variants of viral popula-
tion, being not detected by classical population sequencing.
The powerful ultra-deep pyro-sequencing (UDPS) approach,
based on next generation sequencing (NGS), has been re-
cently used to obtain a complete description of HBV quasis-
pecies, highlighting possible minor populations carrying
mutations in the two overlapping ORFs [6].
This case is relevant for clinical virology because ex-
plores the response to antiviral therapies of a CHB with
concurrent HBsAg and HBsAb positivity, in the absence
of clinically relevant mutations in rt and HBsAg ORFs.
Case presentation
A 59-year-old Italian man was admitted on July 2006 to the
Hepatology Unit of the University Hospital “Campus Bio-
Medico” of Rome, for investigations concerning CHB. He
had not been vaccinated against HBV, he had no known
risk factors for contracting viral hepatitis, and all his house-
holds were negative for HBsAg. At the time of admission,
the virological tests revealed a genotype D hepatitis B enve-
lope antigen (HBeAg) positive CHB with a high viremia
(HBV-DNA), mild elevation of ALT (50 IU/ml) and an un-
expected low titer of HBsAb (26 mIU/ml, with a protective
value above 100 mIU/ml). Anti-hepatitis D and C virus
antibodies were negative.
A serological testing performed three years before was
diagnostic for HBeAg negative CHB with moderate elevation
of ALT (520 IU/ml), medium-low level of HBV-DNA, and
absence of HBsAb, suggesting a subsequent seroreversion
from HBeAg-negativity/anti-HBe positivity to HBeAg posi-
tivity. Till that time, the patient had neither received antiviral
drugs nor indication for repeating virological or liver tests.A liver biopsy was performed showing moderate
necroinflammatory activity and bridging fibrosis (Stage 4/
6 according to Ishak’s Score) [7]. Because the fibrotic evo-
lution, in spite of the genotype D of HBV and the
immune-tolerance phase of CHB, antiviral treatment with
recombinant IFN-alpha-2b (IntronA®) was began at the
dose of 10 MU three times a week. This option was also
supported by clinical guidelines at that time, with an ex-
pected anti-HBe seroconversion rate of about 37% [8].
During treatment, the patient was monitored by three-
monthly blood tests and clinical visits (in Figure 1 six-
monthly blood tests are reported).
After six months of interferon treatment, neither a bio-
chemical response nor a virological response were ob-
served, while HBsAb titer raised to 235 mIU/ml (Figure 1).
Since consistent data about adefovir dipivoxil (ADV) were
already available, the patient was started with ADV (10 mg/
day) [9]. Although, after six months, a partial virological re-
sponse was observed (decrease in HBV DNA of more than
1 log10/ml), after twelve months, a virological breakthrough
was detected (increase in HBV DNA level of more than 1
log10/ml). We were at the beginning of 2007 and the novel
carbocyclic analogue of 2' deoxyguanosine Entecavir (ETV)
had been just licensed, showing outstanding results [10].
Moreover, due to the persistence of HBsAb with high
viremia, mutations in the HBsAg region were investigated.
Conventional sequencing and UDPS of the polymerase
(pol) region of HBV to identify the presence of mutations
in the HBsAg ORF associated to mutations on the overlap-
ping rt ORF, possibly present in minor components of viral
quasispecies, were performed. The methods for UDPS
and elaboration of sequence data have been previously de-
scribed [6]. Some mutations in both rt and HBsAg ORFs
were detected (with frequency varying from 10 to 96%), but
none of these are known to be associated with resistance to
current HBV-specific NAs or to be involved in immuno-
logical escape (Additional file 1: Table S1).
Based on these results, ETV (0.5 mg/day) was added
to ADV and, three months later, HBV-DNA levels be-
came undetectable. On July 2009, after twelve months
of ADV and ETV combination therapy, due to an appar-
ent new virological breakthrough (Figure 1), ADV was re-
placed with the novel nucleotide analogue tenofovir
(TDF). After three months of TDF (245 mg/day) plus
ETV (0.5 mg/day) combination, virological suppression
was achieved. Surprisingly, on January 2011, i.e. six
months later, anti-HBe seroconversion and HBsAg loss
were observed, while the titer of HBsAb persisted. Anti-
HBe seroconversion and HBsAg loss were confirmed after
six months, when antiviral agents were discontinued. Un-
fortunately, the patient died on September 2011 because
of a ruptured thoracic aortic aneurysm, so further follow-
up visits are not available to verify the sustained off-
treatment virological response.
Figure 1 On-treatment virological and biochemical response. LLQ1: Lower limit of quantification (Amplicor HBV-Monitor; Roche Diagnostic
Systems, Branchburg, NJ); LLQ2: Lower limit of quantification (COBAS TaqMan 48; Roche, Branchburg, NJ); IFN: interferon; ETV: entecavir; ADV:
adefovir dipivoxil; TDV: tenofovir. HBsAb quantification (protective value > 100 mIU/ml): Roche Modular Analytics E601 assay.
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This case highlights several observations, both in the
therapeutic approach and in the virological setting.
In particular, there are some clinical and virological
points which deserve consideration: 1) a non-protective
HBsAb titer in high-viremic HBV infection; 2) a difficult-
to-treat infection, both with IFN therapy and with NAs
(ADV and ADV plus ETV); 3) a strong response to second-
generation NAs combination (ETV plus TDV), finally with
seroconversion to anti-HBe and HBsAg loss.
First, the clinical significance of the co-existence of
HBsAg and HBsAb is not well understood, since clinical
data are lacking in most studies. A screening of 411 patients
with CHB from China revealed a relatively high percentage
(4.9%) of detectable serum HBsAb levels, while in a French
study a lower prevalence (3.1%) was observed [11,12]. The
exposure of patients to HBV infection of different subtypes
could not be excluded as a possible explanation of coexist-
ence of HBsAg and HBsAb. The epidemiological import-
ance of such HBV mutants is supported by reports from
Taiwan, where the HBV vaccination program was associ-
ated with an increased prevalence of HBsAg mutants [13].
Later reports suggested that the presence of HBsAb can
drive the selection of HBsAg escape mutants, even if HBV
isolates are often without relevant mutations in the coding
region of HBsAg, such as in our case [3].
Second, only one case of CHB with a population of
HBsAg mutants was described to have seroconversion to
anti-HBe and HBsAg clearance after therapy with peg-
IFN [14]. Nowadays, it is unknown if these cases are
more difficult to cure with standard therapies.
Third, the oral antiviral therapy is able to achieve and
maintain virological suppression during long-term use.
The most powerful combination of NAs, ETV and TDV,
could provide additive or synergistic antiviral activity.Nevertheless, in a study of 379 NAs naïve patients with
HBeAg positive and HBeAg negative CHB, the efficacy
of ETV was comparable to that of ETV plus TDF com-
bination, in term of HBsAg loss and rate of anti-HBe
seroconversion [15]. However, specific data concerning
the response to treatment (both with IFN and NAs) of
CHB with concurrent HBsAg/HBsAb are lacking, and,
from most of clinical studies, results can not even be
extrapolated.
Moreover, our patient experienced a seroreversion
from HBeAg-negativity/anti-HBe positivity to HBeAg
positivity. The appearance and disappearance of HBeAg
may be related to the alternating balance of the host im-
mune control over the viral replication, and it could not
be excluded that subtle changes in the composition of
HBV quasispecies were responsible for the processes of
HBeAg seroconversion and seroreversion, as well as for
the HBsAg/HBsAb coexistence [16].
The virological findings associated with this case re-
main so far unexplained. It is possible that genome alter-
ations were present in regions different from those
analysed in the study. For this reason, the sequencing of
the whole genome would have been probably more in-
formative. Furthermore it is possible that host-associated
factors (i.e. immunological competence, innate immunity
response, gene polymorphisms associated with poor con-
trol of chronic viral infections) may be responsible for
the anomalous response pattern observed in this patient.
Finally, we cannot exclude the coexistence of minor
mutant strains, not detected by UDPS in serum, that
could have been found in the liver or leukocytes.
This is, to our knowledge, the first case described of a
CHB with HBsAg/HBsAb positivity, wild type for muta-
tions clinically relevant in HBsAg and rt ORFs, success-
fully treated with a combination of NAs.
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